Table 2 Positive rate of FISH according to enrichment method in NDMM patients.

From: Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma

  

Direct FISH, % (n/total)

FICTION, % (n/total)

FACS-FISH, % (n/total)

P value

Deletion

17p13.1

5.8%

(8/137)

10.7%

(24/224)

34.9%

(46/132)‡§

 < 0.0001*

13q14.3

19.7%

(27/137)

22.8%

(51/224)

52.3%

(70/131)‡§

 < 0.0001*

Translocation

t(11;14)

5.8%

(8/137)§¶

8.0%

(18/224)‡¶

24.2%

(32/132)‡§

 < 0.0001*

t(4;14)

5.8%

(8/137)

3.1%

(7/224)

9.9%

(13/132)§

0.0299*

t(14;16)

0.0%

(0/137)

0.0%

(0/224)

2.3%

(3/132)

0.0188†

Gains

1q21

17.7%

(11/62)

23.4%

(52/222)

46.2%

(61/132)‡§

 < 0.0001*

Overall positive rate

38.0%

(52/137)‡§

56.3%

(126/224) ‡¶

95.5%

(126/132) ‡§

 < 0.0001*

  1. *Chi-square test.
  2. †Fisher-exact test.
  3. ‡Significant difference with direct FISH (Post hoc test).
  4. §Significant difference with FICTION (Post hoc test).
  5. Significant difference with FACS-FISH (Post hoc test).
  6. NDMM, newly diagnosed multiple myeloma; FISH, fluorescence in situ hybridization; FICTION, fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation of neoplasms; FACS, fluorescence activated cell sorting.
Back to article page